Skip to main content
 

Astute Clinician Lecture

This annual lecture, begun in 1998 and part of the Wednesday Afternoon Lecture Series, honors a U.S. scientist who has observed an unusual occurrence, and by investigating it, has opened an important new avenue of research. The lectureship exemplifies how astute clinical observations can lead to innovative research. Speakers are selected by the NIH Clinicial Center.

Sugar and the beating heart - the conundrum of heart failure in diabetes

February 7, 2018 - 3:00pm to 4:00pm
E. Dale Abel, M.D., Ph.D. , University of Iowa

Dr. Abel's current research interests focus on elucidating the molecular mechanisms leading to cardiac dysfunction in diabetes and the regulation of myocardial growth and metabolism by insulin signaling.

Perspective on autoimmunity: a view from the ANCA vasculitis looking glass

November 2, 2016 - 3:00pm to 4:00pm
Ronald J. Falk, M.D., University of North Carolina - Chapel Hill

Dr. Ronald Falk is internationally recognized physician-scientist whose lifelong career has been the study of autoimmune kidney disease and ANCA vasculitis. For over three decades, his research has led to a deeper understanding of the causes and conditions that may lead to the development of ANCA vasculitis in an effort to improve the lives of those patients afflicted with vasculitis and autoimmune kidney diseases.

Relief from severe depression and suicidal ideation within hours: from synapses to symptoms

November 4, 2015 - 3:00pm to 4:00pm
Carlos Zarate, M.D. , National Institute of Mental Health

Dr. Zarate's current research focus is on developing novel medications for treatment-resistant depression and bipolar disorder. His areas of expertise include biological and pharmacological aspects of mood disorders in adults. Dr. Zarate's group conducts proof-of-concept studies utilizing novel compounds and biomarkers (magnetoencephalography [MEG] and polysomnography [PSG], positron emission tomography, functional MRI and magnetic resonance spectroscopy [MRS]) to identify potentially relevant drug targets and biosignatures of treatment response.

Past and future therapy for hepatitis C

November 12, 2014
Jay H. Hoofnagle, M.D., NIDDK/NIH

The Astute Clinician series honors a U.S. clinician-scientist who has observed an unusual clinical occurrence, and by investigating it, has opened an important new avenue of research. Dr. Jay H. Hoofnagle, an expert in liver diseases, has been involved in early evaluation and development of virtually all antiviral agents developed for viral hepatitis including interferon, ribavirin, lamivudine and adefovir dipivoxil.

The genetic basis of kidney cancer: targeting the metabolic basis of disease

November 20, 2013
W. Marston Linehan, M.D., National Cancer Institute

Dr. Linehan has had a long-standing interest in identification of the genetic basis of cancer of the kidney. Kidney cancer is not a single disease. It is made up of a number of different types of cancer, each of which has a different histology, a different clinical course, which respond differently to therapy and are caused by different genes. Studies of the kidney cancer gene pathways have revealed that kidney cancer is fundamentally a metabolic disease.


The page was last updated on Thursday, January 29, 2015 - 2:31pm